Current Role of Radiotherapy for Renal-Cell Carcinoma

Review

Natalia Dengina, Ilya Tsimafeyeu, Timur Mitin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Surgery is the standard of care for patients with renal-cell carcinoma (RCC). Radiotherapy (RT) can decrease the risk of local recurrence after surgery and can lead to excellent outcomes in patients unfit for surgery. We reviewed clinical experience with various forms of RT, including conventional fractionated RT and intraoperative radiotherapy (IORT) as adjunct to surgery, hypofractionated high-dose stereotactic body radiotherapy (SBRT), and particle therapy in unresectable RCC. We discuss future directions for using RT in the treatment of RCC. We encourage clinicians to incorporate RT modalities in prospective clinical trials.

Original languageEnglish (US)
JournalClinical Genitourinary Cancer
DOIs
StateAccepted/In press - Jul 7 2016

Fingerprint

Renal Cell Carcinoma
Radiotherapy
Radiosurgery
Standard of Care
Clinical Trials
Recurrence
Therapeutics

Keywords

  • Intraoperative radiotherapy
  • Particle therapy
  • Radioresistance
  • Radiosensitivity
  • Stereotactic body radiotherapy
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Current Role of Radiotherapy for Renal-Cell Carcinoma : Review. / Dengina, Natalia; Tsimafeyeu, Ilya; Mitin, Timur.

In: Clinical Genitourinary Cancer, 07.07.2016.

Research output: Contribution to journalArticle

@article{da53974f3ae24617bc0c6ce75d09d6c4,
title = "Current Role of Radiotherapy for Renal-Cell Carcinoma: Review",
abstract = "Surgery is the standard of care for patients with renal-cell carcinoma (RCC). Radiotherapy (RT) can decrease the risk of local recurrence after surgery and can lead to excellent outcomes in patients unfit for surgery. We reviewed clinical experience with various forms of RT, including conventional fractionated RT and intraoperative radiotherapy (IORT) as adjunct to surgery, hypofractionated high-dose stereotactic body radiotherapy (SBRT), and particle therapy in unresectable RCC. We discuss future directions for using RT in the treatment of RCC. We encourage clinicians to incorporate RT modalities in prospective clinical trials.",
keywords = "Intraoperative radiotherapy, Particle therapy, Radioresistance, Radiosensitivity, Stereotactic body radiotherapy, Targeted therapy",
author = "Natalia Dengina and Ilya Tsimafeyeu and Timur Mitin",
year = "2016",
month = "7",
day = "7",
doi = "10.1016/j.clgc.2016.09.004",
language = "English (US)",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",

}

TY - JOUR

T1 - Current Role of Radiotherapy for Renal-Cell Carcinoma

T2 - Review

AU - Dengina, Natalia

AU - Tsimafeyeu, Ilya

AU - Mitin, Timur

PY - 2016/7/7

Y1 - 2016/7/7

N2 - Surgery is the standard of care for patients with renal-cell carcinoma (RCC). Radiotherapy (RT) can decrease the risk of local recurrence after surgery and can lead to excellent outcomes in patients unfit for surgery. We reviewed clinical experience with various forms of RT, including conventional fractionated RT and intraoperative radiotherapy (IORT) as adjunct to surgery, hypofractionated high-dose stereotactic body radiotherapy (SBRT), and particle therapy in unresectable RCC. We discuss future directions for using RT in the treatment of RCC. We encourage clinicians to incorporate RT modalities in prospective clinical trials.

AB - Surgery is the standard of care for patients with renal-cell carcinoma (RCC). Radiotherapy (RT) can decrease the risk of local recurrence after surgery and can lead to excellent outcomes in patients unfit for surgery. We reviewed clinical experience with various forms of RT, including conventional fractionated RT and intraoperative radiotherapy (IORT) as adjunct to surgery, hypofractionated high-dose stereotactic body radiotherapy (SBRT), and particle therapy in unresectable RCC. We discuss future directions for using RT in the treatment of RCC. We encourage clinicians to incorporate RT modalities in prospective clinical trials.

KW - Intraoperative radiotherapy

KW - Particle therapy

KW - Radioresistance

KW - Radiosensitivity

KW - Stereotactic body radiotherapy

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85005993313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85005993313&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2016.09.004

DO - 10.1016/j.clgc.2016.09.004

M3 - Article

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

ER -